Fintel reports that on February 11, 2025, Deutsche Bank initiated coverage of Praxis Precision Medicines (NasdaqGS:PRAX) with a Buy recommendation.
Analyst Price Forecast Suggests 100.32% Upside
As of January 29, 2025, the average one-year price target for Praxis Precision Medicines is $168.81/share. The forecasts range from a low of $57.57 to a high of $320.25. The average price target represents an increase of 100.32% from its latest reported closing price of $84.27 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Praxis Precision Medicines is 0MM, a decrease of 100.00%. The projected annual non-GAAP EPS is -3.12.
What is the Fund Sentiment?
There are 300 funds or institutions reporting positions in Praxis Precision Medicines. This is an increase of 72 owner(s) or 31.58% in the last quarter. Average portfolio weight of all funds dedicated to PRAX is 0.24%, an increase of 9.83%. Total shares owned by institutions increased in the last three months by 15.71% to 22,184K shares.
What are Other Shareholders Doing?
Perceptive Advisors holds 1,164K shares representing 6.00% ownership of the company. In its prior filing, the firm reported owning 750K shares , representing an increase of 35.55%. The firm increased its portfolio allocation in PRAX by 89.60% over the last quarter.
Price T Rowe Associates holds 1,120K shares representing 5.78% ownership of the company. In its prior filing, the firm reported owning 939K shares , representing an increase of 16.20%. The firm increased its portfolio allocation in PRAX by 59.74% over the last quarter.
Point72 Asset Management holds 1,033K shares representing 5.33% ownership of the company. In its prior filing, the firm reported owning 1,052K shares , representing a decrease of 1.79%. The firm increased its portfolio allocation in PRAX by 32.76% over the last quarter.
Capital Research Global Investors holds 997K shares representing 5.14% ownership of the company.
SMCWX - SMALLCAP WORLD FUND INC holds 888K shares representing 4.58% ownership of the company.
Praxis Precision Medicines Background Information
(This description is provided by the company.)
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance. Praxis is applying insights from genetic epilepsies to broader neurological and psychiatric disorders, using our understanding of shared biological targets and circuits in the brain. Praxis has established a broad portfolio, including multiple disclosed programs across CNS disorders including depression, epilepsy, movement disorders and pain syndromes, with three clinical-stage product candidates.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
